Ipsen’s Onivyde^® Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen announced that the US FDA has approved the supplemental new drug application for Onivyde® plus oxaliplatin, fluorouracil, and leucovorin as a first-line treatment in adults living with metastatic pancreatic adenocarcinoma.